Please login to the form below

Not currently logged in
Email:
Password:

Chiltern International lines up Dr Jim Esinhart as next CEO

He will replace Glenn Kerkhof from November 1, 2012

Chiltern International has selected Dr Jim Esinhart to be its next CEO with effect from November 1, 2012.

He will replace Glenn Kerkhof, who is stepping down as CEO of the London-based contract research organisation (CRO) after six years in the post.

Kerkhof will relocate to his native Australia to lead Chiltern's owner Czura Thornton in Asia Pacific, but will join Chiltern's board of directors.

Chiltern's new CEO Dr Esinhart has been with the company for six years and is currently senior executive vice president of global scientific services.

Kerkhof said: “I am delighted to have played my part in the development of Chiltern as a leading mid-tier CRO. Chiltern now employs more than 1,400 people in 34 countries, is financially very strong and is poised for substantial growth.

“I am also delighted to see the CEO position transition to a valued and trusted colleague in Jim Esinhart, who I know will bring a tremendous amount to the role. And I very much look forward to contributing to Chiltern's future as a member of the Board based in the Asia Pacific region.”

9th October 2012

From: PME

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics